Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were r...
Saved in:
| Published in | Multiple sclerosis journal - experimental, translational and clinical Vol. 7; no. 4; p. 20552173211052656 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London, England
SAGE Publications
01.10.2021
Sage Publications Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2055-2173 2055-2173 |
| DOI | 10.1177/20552173211052656 |
Cover
| Abstract | Objective
Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD).
Methods
We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria.
Results
Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive.
Conclusions
AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting. |
|---|---|
| AbstractList | Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting. Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting. Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD).OBJECTIVEDetermine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD).We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria.METHODSWe included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria.Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive.RESULTSOf 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive.AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.CONCLUSIONSAQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting. Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting. |
| Author | Weinshenker, Brian G. Tariq Bhatti, M. Flanagan, Eoin P. Montalvo, Mayra Fryer, James P. Lennon, Vanda A. Mills, John R. Wingerchuk, Dean M. Redenbaugh, Vyanka McKeon, Andrew Lopez Chiriboga, A. Sebastian Sechi, Elia Buciuc, Marina Chen, John J. Pittock, Sean J. |
| Author_xml | – sequence: 1 givenname: Vyanka orcidid: 0000-0001-6400-7760 surname: Redenbaugh fullname: Redenbaugh, Vyanka organization: , Rochester, MN, USA – sequence: 2 givenname: Mayra surname: Montalvo fullname: Montalvo, Mayra organization: , Rochester, MN, USA – sequence: 3 givenname: Elia orcidid: 0000-0003-4698-663X surname: Sechi fullname: Sechi, Elia organization: , Sassari, Italy – sequence: 4 givenname: Marina surname: Buciuc fullname: Buciuc, Marina organization: , Rochester, MN, USA – sequence: 5 givenname: James P. surname: Fryer fullname: Fryer, James P. organization: , Rochester, MN, USA – sequence: 6 givenname: Andrew surname: McKeon fullname: McKeon, Andrew organization: , Rochester, MN, USA – sequence: 7 givenname: Vanda A. surname: Lennon fullname: Lennon, Vanda A. organization: , Rochester, MN, USA – sequence: 8 givenname: John R. surname: Mills fullname: Mills, John R. organization: , Rochester, MN, USA – sequence: 9 givenname: Brian G. surname: Weinshenker fullname: Weinshenker, Brian G. organization: , Rochester, MN, USA – sequence: 10 givenname: Dean M. surname: Wingerchuk fullname: Wingerchuk, Dean M. organization: , Scottsdale, AZ, USA – sequence: 11 givenname: John J. surname: Chen fullname: Chen, John J. organization: , Rochester, MN, USA – sequence: 12 givenname: M. surname: Tariq Bhatti fullname: Tariq Bhatti, M. organization: , Rochester, MN, USA – sequence: 13 givenname: A. Sebastian orcidid: 0000-0001-5653-5600 surname: Lopez Chiriboga fullname: Lopez Chiriboga, A. Sebastian organization: , Jacksonville, FL, USA – sequence: 14 givenname: Sean J. orcidid: 0000-0002-8387-6491 surname: Pittock fullname: Pittock, Sean J. organization: , Rochester, MN, USA – sequence: 15 givenname: Eoin P. orcidid: 0000-0002-6661-2910 surname: Flanagan fullname: Flanagan, Eoin P. email: flanagan.eoin@mayo.edu organization: , Rochester, MN, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34868626$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUFv1DAQhS1UREvpD-CCLHHhkuKxYzt7QUIFSqVKXOBsOc5kcZXYqZ2stP--jraUUgQnW-PvPb3neUmOQgxIyGtg5wBav-dMSg5acAAmuZLqGTlZZ9U6PHp0PyZnOd8wxkCqMoQX5FjUjWoUVyek--TtNsQ8e0d3dliQxp7a28VOMflQ1dXV9pIOfofU4TDQ1mbsqM3Z7qkPNOCS4rjHwc8-0zgVF0vzhG5Oy0g7n2PqMOVX5Hlvh4xn9-cp-fHl8_eLr9X1t8uri4_XlauVmivlOhS63_TK9S2vN23juGwR0eoSdwMdStHpplWi5QJQ29o5xcoHyAbAARen5MPBd1raETuHYU52MFPyo017E603f74E_9Ns4840SmgNqhi8uzdI8XbBPJvR57W4DRiXbLhiWrBNI1f07RP0Ji4plHqFAsFFI6Au1JvHiR6i_FpAAeAAuBRzTtg_IMDMumfz156LRj_ROD_b2ce1lB_-qzw_KLPd4u_A_xbcAVO6uIc |
| CitedBy_id | crossref_primary_10_1002_ana_26722 crossref_primary_10_3389_fneur_2022_866824 crossref_primary_10_1001_jamaneurol_2023_2974 crossref_primary_10_1111_ene_15983 crossref_primary_10_1080_14728222_2023_2240017 crossref_primary_10_1002_glia_24675 crossref_primary_10_1177_13524585251313744 crossref_primary_10_3389_fneur_2022_885218 crossref_primary_10_17816_ACEN_1124 crossref_primary_10_3389_fneur_2022_912050 crossref_primary_10_3389_fneur_2024_1326867 crossref_primary_10_1212_NXI_0000000000200329 crossref_primary_10_1212_WNL_0000000000206820 |
| Cites_doi | 10.1016/j.msard.2021.103030 10.1111/bpa.12084 10.1001/jamaneurol.2020.2743 10.1136/jnnp-2015-312601 10.3389/fneur.2019.01028 10.1212/WNL.0000000000001729 10.1212/NXI.0000000000000231 10.1001/jamaneurol.2021.0912 10.1212/WNL.0b013e3182a6cb5c 10.1212/NXI.0000000000000011 |
| ContentType | Journal Article |
| Copyright | The Author(s), 2021 The Author(s), 2021. The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| Copyright_xml | – notice: The Author(s), 2021 – notice: The Author(s), 2021. – notice: The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| DBID | AFRWT AAYXX CITATION NPM 7X7 7XB 8FI ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1177/20552173211052656 |
| DatabaseName | Sage Journals GOLD Open Access 2024 CrossRef PubMed Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: AFRWT name: Sage Journals GOLD Open Access 2024 url: http://journals.sagepub.com/ sourceTypes: Publisher – sequence: 3 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2055-2173 |
| ExternalDocumentID | PMC8637716 34868626 10_1177_20552173211052656 10.1177_20552173211052656 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G 54M 5VS 7X7 8FI AAJPV AASGM ABAWP ABNCE ABQXT ABVFX ACARO ACGFS ACROE ADBBV ADOGD AEUHG AEWDL AFCOW AFKRA AFKRG AFRWT AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AUTPY AYAKG BCNDV BDDNI BENPR BPHCQ BSEHC BVXVI CCPQU DC. EBS EJD EMOBN FYUFA GROUPED_DOAJ H13 HMCUK HYE J8X K.F O9- OK1 PHGZM PHGZT PIMPY PQQKQ ROL RPM SAUOL SCDPB SCNPE SFC UKHRP AAYXX ACHEB CITATION NPM 7XB ABUWG AZQEC DWQXO PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c466t-6cde37f9f6cfb249b8c25beeea786891de53d78b63b231e7a4cc603215811c123 |
| IEDL.DBID | AFRWT |
| ISSN | 2055-2173 |
| IngestDate | Thu Aug 21 14:12:21 EDT 2025 Thu Sep 04 22:11:13 EDT 2025 Sun Jun 29 15:55:52 EDT 2025 Thu Apr 03 06:58:54 EDT 2025 Tue Jul 01 05:26:42 EDT 2025 Thu Apr 24 23:06:56 EDT 2025 Tue Jun 17 22:32:51 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). The Author(s), 2021. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c466t-6cde37f9f6cfb249b8c25beeea786891de53d78b63b231e7a4cc603215811c123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 VR and MM are joint first authors. |
| ORCID | 0000-0002-6661-2910 0000-0001-6400-7760 0000-0001-5653-5600 0000-0003-4698-663X 0000-0002-8387-6491 |
| OpenAccessLink | https://journals.sagepub.com/doi/full/10.1177/20552173211052656?utm_source=summon&utm_medium=discovery-provider |
| PMID | 34868626 |
| PQID | 2613238314 |
| PQPubID | 4451081 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8637716 proquest_miscellaneous_2607309856 proquest_journals_2613238314 pubmed_primary_34868626 crossref_primary_10_1177_20552173211052656 crossref_citationtrail_10_1177_20552173211052656 sage_journals_10_1177_20552173211052656 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-01 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: United States – name: Thousand Oaks – name: Sage UK: London, England |
| PublicationTitle | Multiple sclerosis journal - experimental, translational and clinical |
| PublicationTitleAlternate | Mult Scler J Exp Transl Clin |
| PublicationYear | 2021 |
| Publisher | SAGE Publications Sage Publications Ltd |
| Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd |
| References | Waters, Reindl, Saiz 2016; 87 Jarius, Wildemann 2013; 23 Fryer, Lennon, Pittock 2014; 1(1):e11 Jiao, Fryer, Lennon 2013; 81 Prain, Woodhall, Vincent 2019; 10 Wingerchuk, Banwell, Bennett 2015; 85 Kunchok, Chen, Saadeh 2020; 77 Majed, Fryer, McKeon 2016; 3 Li, Zhang, Jia 2021; 53 bibr9-20552173211052656 bibr10-20552173211052656 bibr1-20552173211052656 bibr7-20552173211052656 bibr4-20552173211052656 bibr3-20552173211052656 bibr5-20552173211052656 bibr8-20552173211052656 bibr6-20552173211052656 bibr2-20552173211052656 |
| References_xml | – volume: 77 start-page: 1572 year: 2020 end-page: 1575 article-title: Application of 2015 seronegative neuromyelitis Optica Spectrum disorder diagnostic criteria for patients With myelin oligodendrocyte glycoprotein IgG–associated disorders publication-title: JAMA Neurol – volume: 87 start-page: 1005 year: 2016 end-page: 1015 article-title: Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica publication-title: J Neurol Neurosurg Psychiatry – volume: 53 start-page: 103030 year: 2021 article-title: The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative neuromyelitis Optica Spectrum disorder: a systematic review and meta-analysis publication-title: Mult Scler Relat Disord – volume: 81 start-page: 1197 year: 2013 end-page: 1204 article-title: Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica publication-title: Neurology – volume: 3 year: 2016 article-title: Clinical utility of testing AQP4-IgG in CSF: guidance for physicians publication-title: Neurology-Neuroimmunology Neuroinflammation – volume: 1(1):e11 year: 2014 article-title: AQP4 Autoantibody assay performance in clinical laboratory service publication-title: Neurology-Neuroimmunology Neuroinflammation – volume: 85 start-page: 177 year: 2015 end-page: 189 article-title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders publication-title: Neurology – volume: 10 start-page: 1028 year: 2019 article-title: AQP4 Antibody assay sensitivity comparison in the Era of the 2015 diagnostic criteria for NMOSD publication-title: Front Neurol – volume: 23 start-page: 661 year: 2013 end-page: 683 article-title: Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature publication-title: Brain Pathol – ident: bibr7-20552173211052656 doi: 10.1016/j.msard.2021.103030 – ident: bibr4-20552173211052656 doi: 10.1111/bpa.12084 – ident: bibr8-20552173211052656 doi: 10.1001/jamaneurol.2020.2743 – ident: bibr2-20552173211052656 doi: 10.1136/jnnp-2015-312601 – ident: bibr3-20552173211052656 doi: 10.3389/fneur.2019.01028 – ident: bibr6-20552173211052656 doi: 10.1212/WNL.0000000000001729 – ident: bibr10-20552173211052656 doi: 10.1212/NXI.0000000000000231 – ident: bibr5-20552173211052656 doi: 10.1001/jamaneurol.2021.0912 – ident: bibr9-20552173211052656 doi: 10.1212/WNL.0b013e3182a6cb5c – ident: bibr1-20552173211052656 doi: 10.1212/NXI.0000000000000011 |
| SSID | ssj0001562051 |
| Score | 2.3376372 |
| Snippet | Objective
Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD).
Methods
We... Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). We included Mayo... Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We... Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD).OBJECTIVEDetermine the... |
| SourceID | pubmedcentral proquest pubmed crossref sage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 20552173211052656 |
| SubjectTerms | Aquaporins Brief Report |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSwMxEA4-Ll5E8VWtEkEQhMVmk02yJxHfHjxZ6K3ktSrobmvbg__emW3aWoo97ib7yEwyr0y-IeRMmszmIgAHQEKig8ISU2Qs8brIpUmdZqbO8n2Rj23x3Mk6MeA2iGmVE5lYC2pfOYyRX4Klz0G9cCauev0Eq0bh7mosobFK1hlYIli6QXXULMYCyh0mXdzMRJwluAR9pTi6PQgML-fV0YKNuZgq-Sffq1ZB91tkM9qO9HrM7G2yEsod4m_HyXJwjyJyd6BVQU1_ZHqYWpeI5OntgX6CTKMYo6eotTwFi9n80I-S1nCWXz8Bk-AGtOphZJvWpy-_R1_UR2jOwS5p39-93jwmsXRC4oSUw0Q6H7gq8kK6woKHZbVLMxtCMEpLnTMfMu6VtpJbMPCCMsI52QKyZJoxB9psj6yVVRkOCJUmb1nQ4144I3zKjfIZg0eLXNg0Na0GaU0o2HURVxzLW3x2WYQSXyB6g1xMH-mNQTWWdW5O2NKN62vQnc2GBjmdNsPKQFKaMlQj7IPiK9f4iv0xF6df40Lj0RhoUXP8nXZA1O35lvLjvUbf1pIrcDIb5BxnwuyX_h3A4fIBHJGNFJdInSDYJGvA33AMhs7QntSz-Rfuxvh_ priority: 102 providerName: ProQuest |
| Title | Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders |
| URI | https://journals.sagepub.com/doi/full/10.1177/20552173211052656 https://www.ncbi.nlm.nih.gov/pubmed/34868626 https://www.proquest.com/docview/2613238314 https://www.proquest.com/docview/2607309856 https://pubmed.ncbi.nlm.nih.gov/PMC8637716 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELb6uHBBoPJYKCsjISEhBZLYsZ0TakuXwqFCVSv2FvmVUqmbLOzmsP-eGcfZslqKOEWKnTiZsT0Pf_5MyBuhC1NyDxqAGRIDlCzRdZElTtWl0LlVmQ4o33NxdsW_TovpDmmHvTBRgov3CKuCLwqTNY5uzEZ_iIuMELEXYHYkw-gF-d3Fx245q_p093CqBt7B9eluhkvbFgGRq2TY3rZL9pG6HIbE_tHk4vvlXVoG_IE0HNqIbSTYSFwL_Wu7m9Zsy0XdRlr-ARcLFmzyiDyMric96vvKY7LjmwPiPvVYO7hHkfjb07am-men54jMS3jy5fozvYUpkWKKn6LRcxQcbr2iNw0NbJizlUcM3YK2c0yM07B581c3oy4yey6ekKvJ6eXJWRJPXkgsF2KZCOs8k3VZC1sbCNCMsnlhvPdaKqHKzPmCOamMYAb8Qy81t1akIJZCZZkFY_iU7DVt458TKnSZGnADHLeau5xp6YoMHq1LbvJcpyOSDhKsbKQlx9MxbqssMpFvCX1E3q0fmfecHP-qfDiopRo6VwVhIwNfhWV8RF6vi2FgoSh149sO6-DsVyp8xbNei-vWGFe4swZK5IZ-1xWQtHuzpLn5Eci7lWASYtQReYs94e6T7v2BF_9d8yV5kONgC1DDQ7IHqvavwGVamjHZlVM5jp0drsen598uxiEB8RtKwhFx |
| linkProvider | SAGE Publications |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9N3QO8ICa-OgYYCYSEFFHHjuM8TGiftGxUCG3S3oJjOzBpSzq6auo_x9_GXeq0qyr2tsfEzod95_vy-XcA75RJikx6pABKSHJQeGTKhEdOl5kysdXcNFm-Q9U_lV_PkrM1-NuehaG0ylYmNoLa1ZZi5J_Q0heoXgSXn0dXEVWNot3VtoSGCaUV3HYDMRYOdhz56Q26cOPtwT7S-30cHx6c7PWjUGUgslKp60hZ50VaZqWyZYHOSKFtnBTee5NqpTPufCJcqgslCrSFfGqktaonUFVqzi0n4ANUAeuSAigdWN89GH7_sYjyoHmBbB-2UwnpCS9RY6aCHC-CplfLCnHFyl1N1ryVcdYowcPH8ChYr2xnxm4bsOarJ-D2Z-l6eI8RdrhndcnM1cSMKLkvktHg1xd2gVKV0S4BI73pGNrsZsrOK9YAal5OPaXhjVk9otg6a85__plcMhfAQcdP4fRepvUZdKq68i-AKZP1CrQknLRGuliY1CUcHy0zWcSx6XWh185gbgOyORXYuMh5ADNfmfQufJw_MprBetzVeaslSx5W-Dhf8GMX3s6bcW3SVJrK1xPqQwI00_SK5zMqzr8mpKbDOdiSLtF33oFwv5dbqvPfDf63ViJFN7cLH4gTFr_03wFs3j2AN_Cgf_LtOD8eDI9ewsOYFmyTrrgFHaS1f4Vm13XxOvA2g5_3vZz-AQ1MPEg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-xVkJ7mZiArWOAkZCQkMLi2HGcx4mtrIAmhFqxt8hf2SZtabeuD_vvuUvdjqoM8RrfOcmd7fvw-WeA98rktpQBNYArJAUoPDF1zhOv61KZzGlu2irfU3Uykl_P8rOYcKOzMFGC009UVoVf1C7WNLsnvj6Ie4wYsOdodQpBwQvBu6sN6GJYo9MOdA_7P38NH7IsaN7T9g5G4kmIKW5t_rWfVeO05nGuF07-Uf3VGqT-M9iKniQ7nKt-G56E5jn4o3npHD5jhOMd2Lhm5mZmJlRol8hkcP6FXeEKxyhjz8iGeYb-s7lnlw1rwS2v7wOVxE3ZeEJ5btaexbydXTMfgTqnL2DUPx5-PkniRQqJk0rdJcr5IIq6rJWrLcZbVrsstyEEU2ilS-5DLnyhrRIW3b1QGOmcSlEsuebcoW17CZ1m3IRdYMqUqUWr7qUz0mfCFD7nyFqX0maZSXuQLiRYuYgyTpddXFU8AouvCb0HH5cskznExr-I9xdqqRZjpcIoUKDrIbjswbtlM84TEqVpwnhGNLSYlZq62Jlrcfk2ITUdlMGWYkW_SwLC4F5taS4vWixurUSBIWcPPtBIePikR39g778p38LTH0f96vvg9Nsr2MxoGrVFhPvQQa2H1-gM3dk3ccT_BmpM_Gk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+value+of+aquaporin-4-IgG+live+cell+based+assay+in+neuromyelitis+optica+spectrum+disorders&rft.jtitle=Multiple+sclerosis+journal+-+experimental%2C+translational+and+clinical&rft.au=Redenbaugh%2C+Vyanka&rft.au=Montalvo%2C+Mayra&rft.au=Sechi%2C+Elia&rft.au=Buciuc%2C+Marina&rft.date=2021-10-01&rft.pub=SAGE+Publications&rft.eissn=2055-2173&rft.volume=7&rft.issue=4&rft_id=info:doi/10.1177%2F20552173211052656&rft_id=info%3Apmid%2F34868626&rft.externalDocID=PMC8637716 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2055-2173&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2055-2173&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2055-2173&client=summon |